Open Navigation

Your contact for everything relating to press, events and news:

 

Ulrich von Rotenhan
Head of Communications & Investor Relations
+49 6172 402 818
press@hqcapital.com

 

June 16, 2021 | Press Release

HQ Capital raises US$210 million co-investment fund Auda Co-Investment Fund II

pdf-Download of the article: here

 

New York/Bad Homburg/Hong Kong, June 16, 2021 – HQ Capital, global private equity specialist, announced the final closing of its co-investment program Auda Co-Investment Fund II (“ACF II” or the “Fund”). With US$210 million of commitments, ACF II surpassed its original target of US$150 million. The limited partners in ACF II consist of high net worth and institutional investors including insurance companies, pension funds and family offices.

 

“With our co-investment program, we offer investors the opportunity to participate directly in select transactions with attractive terms. The high demand for this specialized strategy confirms our approach and is a testament to the confidence our investors have placed in us,” says Dr. Bernd Türk, CEO of HQ Capital.

 

Marc Lohser, Portfolio Manager of ACF II, added: “Auda Co-Investment Fund II is a continuation of our highly successful co-investment strategy that builds on the strong performance of our 2015 predecessor portfolio. We will remain focused on the small and mid-market, and have sized ACF II appropriately to source and execute on deals in this space. We appreciate the strong support from existing and new investors and look forward to continuing to deliver attractive returns for our clients.”

 

ACF II will build a portfolio consisting of 30 to 35 companies primarily in North America that are diversified by sector, strategy, and general partner. HQ Capital will leverage its extensive GP network to identify the best opportunities available in the market and maintain a focus on portfolio construction. HQ Capital has completed over 50 co-investments since 2015 and has become a preferred co-investment partner for small and mid-market GPs.